Cardiovascular Toxicity of Novel HER2-Targeted Agents and Multikinase Inhibitors in Oncology: From Mechanisms to Real-World Clinical Evidence

The advent of novel Human Epidermal growth factor Receptor 2 (HER2)-targeted therapies and tyrosine kinase inhibitors (TKIs) has significantly improved outcomes in HER2-positive malignancies, particularly breast cancer. However, these agents carry a growing burden of cardiovascular adverse events, r...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Amro Abu Suleiman, Vincenzo Quagliariello, Luigi Spadafora, Federico Russo, Nicola Maurea
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	MDPI AG 2026-05-01
Schriftenreihe:	Pharmaceuticals
Schlagworte:	cardio-oncology cardiotoxicity HER2 targeted therapy heart failure trastuzumab
Online-Zugang:	https://www.mdpi.com/1424-8247/19/6/833
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!